Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Extracellular domain of TGFβ type III receptor inhibits angiogenesis and tumor growth in human cancer cells

Abstract

TGFβ overexpression in human cancer cells has been shown to promote tumor progression. In the present study, we sought to determine whether sequestration of endogenous TGFβ by the expression of a soluble TGFβ type III receptor (sRIII), can reduce malignancy in human carcinoma cells and whether the tumor-suppressive activity of sRIII is associated with the inhibition of angiogenesis. Ectopic expression of sRIII significantly inhibited the growth of tumors formed by human colon carcinoma HCT116 and breast carcinoma MDA-MB-435 cells in nude mice. It also reduced the metastatic potential of the MDA-MB-435 cells. Thus, endogenous TGFβ appears to be necessary for the progression of these two carcinomas. Furthermore, when the tumor cells were mixed with Matrigel and embedded subcutaneously in nude mice, the blood volume in Matrigel plugs containing sRIII-expressing cells as indicated by hemoglobin levels was significantly lower than that in Matrigel plugs containing the respective control cells. Blood vessel counts in paraffin sections of the Matrigel plugs containing sRIII-expressing cells were also significantly lower than those in paraffin sections of the Matrigel plugs containing control cells. Treatment of human endothelial cells with a recombinant sRIII significantly inhibited their ability to form a capillary web structure on Matrigel. These results for the first time indicate that the sRIII-induced tumor suppression appears to be in part due to the inhibition of angiogenesis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Andres JL, Stanley K, Cheifetz S, Massague J . 1989 J. Cell Biol. 109: 3137–3145

  • Arteaga CL, Carty-Dugger T, Moses HL, Hurd SD, Pietenpol JA . 1993a Cell Growth Differ. 4: 193–201

  • Arteaga CL, Coffey Jr RJ, Dugger TC, McCutchen CM, Moses HL, Lyons RM . 1990 Cell Growth Differ. 1: 367–374

  • Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT . 1993b J. Clin. Invest. 92: 2569–2576

  • Bandyopadhyay A, Zhu Y, Cibull ML, Bao LW, Chen CG, Sun LZ . 1999 Cancer Res. 59: 5041–5046

  • Boyd DD, Levine AE, Brattain DE, McKnight MK, Brattain MG . 1988 Cancer Res. 48: 2469–2474

  • Brattain MG, Levine AE, Chakrabarty S, Yeoman LC, Willson JK, Long B . 1984 Cancer Metast. Rev. 3: 177–191

  • Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB . 1987 Cancer Res. 47: 936–942

  • Chen C, Wang XF, Sun LZ . 1997 J. Biol. Chem. 272: 12862–12867

  • Chen CR, Kang YB, Massague J . 2001 Proc. Natl. Acad. Sci. USA 98: 992–999

  • Chishima T, Miyagi Y, Wang X, Yamaoka H, Shimada H, Moossa AR, Hoffman RM . 1997 Cancer Res. 57: 2042–2047

  • Elenbaas B, Spirio L, Koerner F, Fleming MD, Zimonjic DB, Donaher JL, Popescu NC, Hahn WC, Weinberg RA . 2001 Genes Dev. 15: 50–65

  • Esparza-Lopez J, Montiel JL, Vilchis-Landeros MM, Okadome T, Miyazono K, Lopez-Casillas F . 2001 J. Biol. Chem. 276: 14588–14596

  • Fajardo LF, Prionas SD, Kwan HH, Kowalski J, Allison AC . 1996 Lab. Invest. 74: 600–608

  • Folkman J . 1972 Ann. Surg. 175: 409–416

  • Folkman J . 1995 Nat. Med. 1: 27–31

  • Fridman R, Kibbey MC, Royce LS, Zain M, Sweeney M, Jicha DL, Yannelli JR, Martin GR, Kleinman HK . 1991 J. Natl. Cancer Inst. 83: 769–774

  • Hanahan D, Folkman J . 1996 Cell 86: 353–364

  • Harlow E, Lane D . 1988 Antibodies – A Laboratory Manual Cold Spring Harbor Laboratory

    Google Scholar 

  • Herbst TJ, McCarthy JB, Tsilibary EC, Furcht LT . 1988 J. Cell Biol. 106: 1365–1373

  • Joseph A, Weiss GH, Jin L, Fuchs A, Chowdhury S, O'Shaugnessy P, Goldberg ID, Rosen EM . 1995 J. Natl. Cancer Inst. 87: 372–377

  • Kleinman HK, McGarvey ML, Liotta LA, Robey PG, Tryggvason K, Martin GR . 1982 Biochemistry 21: 6188–6193

  • Lopez-Casillas F, Cheifetz S, Doody J, Andres JL, Lane WS, Massague J . 1991 Cell 67: 785–795

  • Madri JA, Pratt BM, Tucker AM . 1988 J. Cell Biol. 106: 1375–1384

  • Markowitz SD, Roberts AB . 1996 Cytokine. Growth Factor. Rev. 7: 93–102

  • Massague J . 1990 Annu. Rev. Cell Biol. 6: 597–641

  • Massague J, Blain SW, Lo RS . 2000 Cell 103: 295–309

  • Norgaard P, Hougaard S, Poulsen HS, Spang-Thomsen M . 1995 Cancer Treat. Rev. 21: 367–403

  • Oft M, Heider KH, Beug H . 1998 Curr. Biol. 8: 1243–1252

  • Passaniti A, Taylor RM, Pili R, Guo Y, Long PV, Haney JA, Pauly RR, Grant DS, Martin GR . 1992 Lab. Invest. 67: 519–528

  • Price JE . 1996 Breast Cancer Res. Treat. 39: 93–102

  • Price JE, Polyzos A, Zhang RD, Daniels LM . 1990 Cancer Res. 50: 717–721

  • Reiss M . 1999 Microbes Infect. 1: 1327–1347

  • Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH . 1986 Proc. Natl. Acad. Sci. USA 83: 4167–4171

  • Sun L, Chen C . 1997 J. Biol. Chem. 272: 25367–25372

  • Ueki N, Nakazato M, Ohkawa T, Ikeda T, Amuro Y, Hada T, Higashino K . 1992 Biochim. Biophys. Acta 1137: 189–196

  • Ueki N, Ohkawa T, Yokoyama Y, Maeda J, Kawai Y, Ikeda T, Amuro Y, Hada T, Higashino K . 1993 Jpn. J. Cancer Res. 84: 589–593

  • Vilchis-Landeros MM, Montiel L, Mendoza V, Mendoza-Hernandez G, Lopez-Casillas F . 2001 Biochem. J. 355: 215–222

  • Wang J, Sun L, Myeroff L, Wang X, Gentry LE, Yang J, Liang J, Zborowska E, Markowitz S, Willson JK, Brattain MG . 1995 J. Biol. Chem. 270: 22044–22049

  • Welch DR, Fabra A, Nakajima M . 1990 Proc. Natl. Acad. Sci. USA 87: 7678–7682

  • Yang EY, Moses HL . 1990 J. Cell Biol. 111: 731–741

  • Ye SC, Foster JM, Li WH, Liang JR, Zborowska E, Venkateswarlu S, Gong JG, Brattain MG, Willson JV . 1999 Cancer Res. 59: 4725–4731

  • Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massague J, Mundy GR, Guise TA . 1999 J. Clin. Invest 103: 197–206

Download references

Acknowledgements

We thank Dr Janet Price for giving us MDA-MB-435 cells. F Lopez-Casíllas is an International Research Scholar of the Howard Hughes Medical Institute. This work was supported by NIH Grants CA75253 and CA79683 to L-Z Sun and CA50457 and CA72001 to MG Brattain.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to L-Z Sun.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bandyopadhyay, A., Zhu, Y., Malik, S. et al. Extracellular domain of TGFβ type III receptor inhibits angiogenesis and tumor growth in human cancer cells. Oncogene 21, 3541–3551 (2002). https://doi.org/10.1038/sj.onc.1205439

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205439

Keywords

This article is cited by

Search

Quick links